» Articles » PMID: 22492711

An Analysis of Substitution, Deletion and Insertion Mutations in Cancer Genes

Overview
Specialty Biochemistry
Date 2012 Apr 12
PMID 22492711
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer-associated mutations in cancer genes constitute a diverse set of mutations associated with the disease. To gain insight into features of the set, substitution, deletion and insertion mutations were analysed at the nucleotide level, from the COSMIC database. The most frequent substitutions were c → t, g → a, g → t, and the most frequent codon changes were to termination codons. Deletions more than insertions, FS (frameshift) indels more than I-F (in-frame) ones, and single-nucleotide indels, were frequent. FS indels cause loss of significant fractions of proteins. The 5'-cut in FS deletions, and 5'-ligation in FS insertions, often occur between pairs of identical bases. Interestingly, the cut-site and 3'-ligation in insertions, and 3'-cut and join-pair in deletions, were each found to be the same significantly often (p < 0.001). It is suggested that these features aid the incorporation of indel mutations. Tumor suppressors undergo larger numbers of mutations, especially disruptive ones, over the entire protein length, to inactivate two alleles. Proto-oncogenes undergo fewer, less-disruptive mutations, in selected protein regions, to activate a single allele. Finally, catalogues, in ranked order, of genes mutated in each cancer, and cancers in which each gene is mutated, were created. The study highlights the nucleotide level preferences and disruptive nature of cancer mutations.

Citing Articles

Male aging in germ cells: What are we inheriting?.

Elias-Llumbet A, Lira S, Manterola M Genet Mol Biol. 2025; 47Suppl 1(Suppl 1):e20240052.

PMID: 39969160 PMC: 11837248. DOI: 10.1590/1678-4685-GMB-2024-0052.


Insertion-Deletion Events Are Depleted in Protein Regions with Predicted Secondary Structure.

Yang Y, Braga M, Dean M Genome Biol Evol. 2024; 16(5).

PMID: 38735759 PMC: 11102076. DOI: 10.1093/gbe/evae093.


Towards accurate indel calling for oncopanel sequencing through an international pipeline competition at precisionFDA.

Gong B, Lababidi S, Kusko R, Bouri K, Prezek S, Thovarai V Sci Rep. 2024; 14(1):8165.

PMID: 38589653 PMC: 11001604. DOI: 10.1038/s41598-024-58573-y.


Molecular basis and current insights of atypical Rho small GTPase in cancer.

Huang H, Wang S, Guan Y, Ren J, Liu X Mol Biol Rep. 2024; 51(1):141.

PMID: 38236467 DOI: 10.1007/s11033-023-09140-7.


Transition Mutations in the hTERT Promoter Are Unrelated to Potential i-motif Formation in the C-Rich Strand.

Conrad J, Sowers M, Yap D, Cherryhomes E, Pettitt B, Khanipov K Biomolecules. 2023; 13(9).

PMID: 37759708 PMC: 10526324. DOI: 10.3390/biom13091308.


References
1.
Greenman C, Stephens P, Smith R, Dalgliesh G, Hunter C, Bignell G . Patterns of somatic mutation in human cancer genomes. Nature. 2007; 446(7132):153-8. PMC: 2712719. DOI: 10.1038/nature05610. View

2.
Torkamani A, Schork N . Prediction of cancer driver mutations in protein kinases. Cancer Res. 2008; 68(6):1675-82. DOI: 10.1158/0008-5472.CAN-07-5283. View

3.
Check Hayden E . Cancer complexity slows quest for cure. Nature. 2008; 455(7210):148. DOI: 10.1038/455148a. View

4.
Rogozin I, Pavlov Y . Theoretical analysis of mutation hotspots and their DNA sequence context specificity. Mutat Res. 2003; 544(1):65-85. DOI: 10.1016/s1383-5742(03)00032-2. View

5.
Hodgkinson A, Eyre-Walker A . Variation in the mutation rate across mammalian genomes. Nat Rev Genet. 2011; 12(11):756-66. DOI: 10.1038/nrg3098. View